Division of Endocrinology and Metabolism, Department of Internal Medicine, Korea University College of Medicine, Seoul, South Korea.
Front Endocrinol (Lausanne). 2020 May 21;11:332. doi: 10.3389/fendo.2020.00332. eCollection 2020.
Sarcopenia is defined as the age-related loss of muscle mass and strength or physical performance. Increased amounts of adipose tissue often accompany sarcopenia, a condition referred to as sarcopenic obesity. The prevalence of sarcopenic obesity among adults is rapidly increasing worldwide. However, the lack of a universal definition of sarcopenia limits comparisons between studies. Sarcopenia and obesity have similar pathophysiologic factors, including lifestyle behaviors, hormones, and immunological factors, all of which may synergistically affect the risk of developing a series of adverse health issues. Increasing evidence has shown that sarcopenic obesity is associated with accelerated functional decline and increased risks of cardiometabolic diseases and mortality. Therefore, the identification of sarcopenic obesity may be critical for clinicians in aging societies. In this review, we discuss the effect of sarcopenic obesity on multiple health outcomes and its role as a predictor of these outcomes based on the components of sarcopenia, including muscle mass, muscle strength, and physical performance.
肌少症定义为与年龄相关的肌肉质量和力量或身体机能下降。脂肪组织的增加通常伴随着肌少症，这种情况被称为肌少症性肥胖。肌少症性肥胖在全球成年人中的患病率正在迅速上升。然而，由于缺乏肌少症的通用定义，限制了研究之间的比较。肌少症和肥胖具有相似的病理生理因素，包括生活方式行为、激素和免疫因素，所有这些因素都可能协同影响一系列不良健康问题的风险。越来越多的证据表明，肌少症性肥胖与功能衰退加速以及心血管代谢疾病和死亡率增加有关。因此，肌少症性肥胖的识别对于老龄化社会中的临床医生可能至关重要。在这篇综述中，我们讨论了肌少症性肥胖对多种健康结果的影响及其作为这些结果预测因子的作用，其基础是肌少症的组成部分，包括肌肉质量、肌肉力量和身体机能。
